Lower paraoxonase 1 paraoxonase activity is associated with a worse prognosis in patients with non-ST-segment elevation myocardial infarction in long-term follow-up

Coron Artery Dis. 2022 Nov 1;33(7):515-522. doi: 10.1097/MCA.0000000000001181. Epub 2022 Sep 12.

Abstract

Background: Acute coronary syndrome (ACS) is one of the main manifestations of coronary artery disease, with a higher prevalence and worst prognosis. Oxidative stress is important in atherosclerosis and ACS, and paraoxonase 1 (PON1) is directly related to reducing the effects of oxidative stress on lipoproteins. The present study evaluated the prognostic value of PON1 activity in patients with non-ST-segment elevation ACS [non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina (UA)], included in the ERICO study.

Methods: PON1 paraoxonase activity was determined in serum samples from 485 patients collected on admission. The prognostic value in the follow-up of up to 5 years was evaluated according to cutoff points established by tertiles. Kaplan-Meier curves and Cox regression were used for the analysis of all-cause mortality and cardiovascular mortality.

Results: The sample consisted mainly of elderly patients with a high frequency of cardiovascular risk factors. At follow-up of up to 5 years, there were 126 deaths from all causes (80 deaths from CVD). The lowest tertile of PON1 paraoxonase activity was associated with a higher risk of death in patients with NSTEMI, but not in patients with UA.

Conclusion: PON1 paraoxonase activity has potential prognostic value in patients with NSTEMI.

MeSH terms

  • Acute Coronary Syndrome*
  • Aged
  • Angina, Unstable / diagnosis
  • Aryldialkylphosphatase
  • Follow-Up Studies
  • Humans
  • Non-ST Elevated Myocardial Infarction* / complications
  • Non-ST Elevated Myocardial Infarction* / diagnosis
  • Prognosis
  • ST Elevation Myocardial Infarction* / complications
  • ST Elevation Myocardial Infarction* / diagnosis
  • ST Elevation Myocardial Infarction* / therapy

Substances

  • Aryldialkylphosphatase
  • PON1 protein, human